Abstract 91P
Background
To estimate the optimal adjuvant chemotherapy in patients with high-risk stage II and III colon adenocarcinoma, we use a propensity score-matched (PSM), nationwide, population-based cohort study to estimate different adjuvant treatments in high-risk stage II or stage III colon adenocarcinoma.
Methods
We minimized the confounding effects with PSM of sex, age, pathologic stages, tumor locations, total cycles of chemotherapy, and Charlson comorbidity index in various adjuvant treatments outcomes in patients with high-risk stage II and III resctable colon adenocarcinoma from the Taiwan Cancer Registry database by dividing them as follows: group 1, those undergoing surgery alone; group 2, those undergoing adjuvant fluoropyrimidine alone; group 3, those receiving adjuvant oxaliplatin, fluoropyrimidine, and leucovorin (FOLFOX) and group 4 those receiving adjuvant folinic acid, fluorouracil, irinotecan (FOFIRIL).
Results
In both univariate and multivariate Cox regression analyses, adjusted HRs (aHRs) derived for mortality and 95% confidence intervals (CIs), reported as aHR (95% CI), derived for surgery alone, adjuvant fluoropyrimidine alone, and adjuvant FOLFIRI groups compared with the adjuvant FOLFOX group were 1.55 (1.32-1.82), 1.22 (1.05-1.43), and 2.97 (2.43-3.63), respectively. After stratified subgroup analysis, at high-risk stage II, the aHR (95% CI) derived for mortality was 0.52 (0.30-0.89) for the adjuvant fluoropyrimidine alone group compared with the group 3.
Conclusions
Adjuvant fluoropyrimidine alone were more suitable for patients with high-risk stage II colon adenocarcinoma rather than other adjuvant chemotherapy regimens. Adjuvant FOLFOX could be the optimal regimen for patients with pathologic stage III colon adenocarcinoma whatever elderly, sex, or tumor locations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract